

American Society of Hematology (ASH) Annual Meeting 2020

All-Virtual Event

December 5-8, 2020

POSTER PRESENTATIONS

Authors	Title	Session #	Date/Time/ Location
Morton Coleman, MD, FACP1*, David Jacob Andorsky, MD2 , Abdulraheem Yacoub, MD3, Jason M. Melear, MD4 , Suzanne R. Fanning, DO5 , Kathryn S. Kolibaba, MD6 , Frederick Lansigan, MD7, Christopher M. Reynolds, MD8*, Grzegorz S. Nowakowski, MD9, Mecide Gharibo, MD10, Erin Ahn, MS11*, Ju Li, PhD11*, Mathias J. Rummel, MD, PhD12* and Jeff P. Sharman, MD13	1123 Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance https://ash.confex.com/ash/2020/webprogram/Paper134363.html	Session 623 USOR #13064	Saturday, December 5, 2020, 7:00 AM-3:30 PM
John E. Godwin, MD1, Cesar O. Freytes, MD2, Michael Maris, MD3,4, Don A. Stevens, MD5, Daanish Hoda, MD6, Bassam Mattar, MD7*, Juan C. Varela, MD, PhD8, Mohamad Cherry, MD, MS9, James Essell, MD10 , Jay Courtright, MD11* , Suzanne R. Fanning, DO12 , Habte A. Yimer, MD13 , Nikolaus S. Trede, MD, PhD14*, Marina Youssef, PharmD15*, James Lymp, PhD14* and Carlos Bachier, MD16	1196 Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study https://ash.confex.com/ash/2020/webprogram/Paper136640.html	Session 626 USOR #18104	Saturday, December 5, 2020, 7:00 AM-3:30 PM
Mitul D Gandhi1 , Sheila Shapouri2*, Arliene Ravelo2*, Lavanya Sudharshan3*, April Beeks, MPH3* and Keith L Dawson2	1609 NHL Patients and Nurses in the US Prefer Subcutaneous Rituximab Injection Versus Intravenous Rituximab Infusion: A Real-World Study https://ash.confex.com/ash/2020/webprogram/Paper136543.html	Session 902 HEOR	Saturday, December 5, 2020, 7:00 AM-3:30 PM
Joshua F. Zeidner, MD1, Daniel J. Lee, MD2, Gil Fine, PhD3*, Eunice S. Wang, MD4, Vijaya R. Bhatt, MD5, Andrew Dalovisio, MD6*, Pau Montesinos, MD, PhD7*, Kathryn S. Kolibaba, MD3 , Stephen P. Anthony, DO3, David J. Bearss, PhD3 and B. Douglas Smith, MD8	1045 Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Acute Myeloid Leukemia (AML): Results of Newly Diagnosed High-Risk Exploratory Arm https://ash.confex.com/ash/2020/webprogram/Paper133796.html	Session 616	Saturday, December 5, 2020, 7:00 AM-3:30 PM
Michael Wang, MD1, Javier Munoz, MD2, Andre H. Goy, MD3, Frederick L. Locke, MD4, Caron A. Jacobson, MD5*, Brian T. Hill, MD6, John M. Timmerman, MD7, Houston Holmes8* , Samantha Jaglowski, MD, MPH9, Ian W. Flinn, MD, PhD10, Peter A. McSweeney, MD11*, David B. Miklos, MD, PhD12, John M. Pagel, MD, PhD13, Marie José Kersten, MD, PhD14, Noel Milpied15*, Henry C.H. Fung, MD16*, Max S. Topp, MD17, Roch Houot, MD, PhD18*, Amer Beitinjaneh, MD, MPH, MSc19*, Weimin Peng, PhD20*, Lianqing Zheng, PhD20*, John M. Rossi, MS20*, Swaminathan Murugappan, MD, PhD20*, Ioana Kloos, MD20* and Patrick M. Reagan, MD21	1120 One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma https://ash.confex.com/ash/2020/webprogram/Paper136382.html	Session 623	Saturday, December 5, 2020, 7:00 AM-3:30 PM

Bolded text: US Oncology Research affiliated investigator

*Denotes non-member of the American Society of Hematology

POSTER PRESENTATIONS

Authors	Title	Session #	Date/Time/ Location
Michael Wang, MD1, John M. Rossi, MS2*, Javier Munoz, MD3, Andre H. Goy, MD4, Frederick L. Locke, MD5, Patrick M. Reagan, MD6, Caron A. Jacobson, MD7, Brian T. Hill, MD8, Houston Holmes9* , Samantha Jaglowski, MD, MPH10, Weimin Peng, PhD2*, Lianqing Zheng, PhD2*, Xiang Fang, PhD2*, Allen Xue, PhD2*, Ioana Kloos, MD2* and Adrian Bot, MD, PhD2*	1126 Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial https://ash.confex.com/ash/2020/webprogram/Paper136831.html	Session 623	Saturday, December 5, 2020, 7:00 AM-3:30 PM
Tycel J. Phillips, MD1*, Kristina Yu-Isenberg, PhD, MPH, RPh2*, Nicholas Liu, PharmD2*, Andy Surinach, MPH3*, Carlos Flores, MPH3*, Julie Lisano, PharmD2*, Michelle A. Fanale, MD2 and John M. Burke, MD4	2499 Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching https://ash.confex.com/ash/2020/webprogram/Paper140534.html	Session 902 USOR #12176	Sunday, December 6, 2020, 7:00 AM-3:30 PM
John F. Seymour, MBBS1, John G. Gribben, MD, DSc, FRCP, FRCPATH, FMedSci2, Matthew S. Davids, MD3, Anthony Mato, MD4*, Jeff P. Sharman, MD5 , Aimee Cyr6*, Cynthia Bartkus6*, German Pena, MD6*, Michelle Boyer7*, Simon Sharmokh, MPH, PharmD8*, Tanya S. Rosenberg, MD6* and William G. Wierda, MD, PhD9	2231 Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings https://ash.confex.com/ash/2020/webprogram/Paper134938.html	Session 642 USOR #17106	Sunday, December 6, 2020, 7:00 AM-3:30 PM
Anthony Mato, MD1*, Boxiong Tang, MD, PhD2, Soraya Azmi, MBBS, MPH2*, Keri Yang, PhD, MPH, MS2*, Jennifer C. Stern, PhD3*, Eric Hedrick, MD3, Jane Huang, MD4* and Jeff P. Sharman, MD5	2498 A Clinical Practice Comparison of Overall Survival, Time-to-Next-Treatment, and Time-to-Treatment-Discontinuation Among CLL/SLL Patients Receiving First-Line Ibrutinib with and without a Del(17p) Mutation https://ash.confex.com/ash/2020/webprogram/Paper134119.html	Session 902 USOR #18155	Sunday, December 6, 2020, 7:00 AM-3:30 PM
Nancy L. Bartlett, MD1*, Christopher A. Yasenck, MD2 , Robert B. Sims, MD3 and Grzegorz S. Nowakowski, MD4	2112 Trial-in-Progress: Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) https://ash.confex.com/ash/2020/webprogram/Paper136400.html	Session 626 USOR #20144	Sunday, December 6, 2020, 7:00 AM-3:30 PM
Christopher A. Yasenck, MD1 , Jamiya Clark, PhD, MPH2*, Nicholas Liu, PharmD3*, April Beeks, MPH4*, Michelle A. Fanale, MD3, Nicholas Robert, MDCM4* and Kristina Yu-Isenberg, PhD, MPH, RPh3*	2033 Real-World Adherence to National Comprehensive Cancer Network (NCCN) Guidelines Regarding the Usage of PET/CT and Reported Deauville Scores in Advanced Stage Classical Hodgkin Lymphoma: A Community Oncology Practice Perspective https://ash.confex.com/ash/2020/webprogram/Paper140698.html	Session 622 HEOR	Sunday, December 6, 2020, 7:00 AM-3:30 PM
Amer M. Zeidan, MBBS, MHS1, Tara Lin, MD2, Pamela S. Becker, MD, PhD3, Gary J. Schiller, MD4, Prapti Patel, MD5, Alexander I. Spira, PhD, MD, FACP6* , Michaela L. Tsai, MD7* , Errin Samuëlsz8*, Sandra L Silberman, MD, PhD9, Maya Ridinger8*, Mark Erlander, PhD8* and Eunice S. Wang, MD10	1954 Updated Analyses of a Phase 1b/2 Study of Onvansertib, a PLK1 Inhibitor, in Combination with Decitabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia https://ash.confex.com/ash/2020/webprogram/Paper134918.html	Session 616	Sunday, December 6, 2020, 7:00 AM-3:30 PM

Bolded text: US Oncology Research affiliated investigator

*Denotes non-member of the American Society of Hematology

POSTER PRESENTATIONS

Authors	Title	Session #	Date/Time/ Location
Lisa La1, Sundar Jagannath, MD1*, Sikander Ailawadhi, MD2, Brian G.M. Durie, MD3, Cristina J. Gasparetto, MD4*, James W. Hardin, PhD5*, Hans C. Lee, MD6, Mohit Narang, MD7*, James L. Omel, MD8*, Robert M. Rifkin, MD9 , Howard R. Terebelo, DO10, Kathleen Toomey, MD11*, Lynne I. Wagner, PhD12*, Mazaher Dhalla, PharmD13*, Liang Liu, MS13*, Ling Yang, MS13*, Prashant Joshi, MD13* and Rafat Abonour, MD14	3244 Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect® MM Registry https://ash.confex.com/ash/2020/webprogram/Paper137309.html	Session 653 USOR #9141	Monday, December 7, 2020, 7:00 AM-3:30 PM
Pier Luigi Zinzani, MD1, Felipe Samaniego, MD2, Wojciech Jurczak, MD, PhD3, Nilanjan Ghosh, MD, PhD4, Enrico Derenzini, MD, PhD5*, James A Reeves, MD6*, Wanda Knopinska-Posluszny, MD, PhD7*, Chan Yoon Cheah, MBBS8, Tycel J. Phillips, MD9, Ewa Lech-Marañada, MD, PhD10*, Bruce D. Cheson, MD11, Paolo F Caimi, MD12, Sebastian Grosicki, MD, PhD13, Lori A. Leslie, MD14, Julio C. Chavez, MD15, Gustavo A. Fonseca, MD16, Sunil Babu17*, Daniel J. Hodson, MD, PhD18, Spencer H. Shao, MD19, John M. Burke, MD20, Jeff P. Sharman, MD21 , Jennie Y. Law, MD22, John M. Pagel, MD PhD23, Owen A. O'Connor, MD, PhD24, Hari P. Miskin, MSc25*, Peter Sportelli, BS 25, Michael S. Weiss25* and Nathan H Fowler, MD2	2934 Umbralisib, the Once Daily Dual Inhibitor of PI3K δ and Casein Kinase-1 ϵ Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial https://ash.confex.com/ash/2020/webprogram/Paper134851.html	Session 623 USOR #16065	Monday, December 7, 2020, 7:00 AM-3:30 PM
Ian W. Flinn, MD, PhD1, David Andorsky, MD, PhD2* , Jason M. Melear, MD3, Sudhir Manda, MD4 , Bertrand M. Anz III, MD5*, Kathryn Kolibaba, MD6* , Habte A. Yimer, MD7, John M. Burke, MD8, Suzanne R. Fanning, DO9, Jay Courtright, MD10* , Miguel Islas-Ohlmayer, MD11* , Suman Kambhampati, MD12*, Daniel Dingfeng Jiang, MD, PhD13*, John C. Pesko, PhD13*, Tamas Vizkelety, MD13*, Simon Sharmokh, MPH, PharmD13* and Jeff P. Sharman, MD14	3151 Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study https://ash.confex.com/ash/2020/webprogram/Paper137406.html	Session 642 USOR #17106	Monday, December 7, 2020, 7:00 AM-3:30 PM
Nirav N. Shah, MD1, Ahmad H. Mattour, MD2, Leslie L. Popplewell, MD, FACP3, Charalambos Andreadis, MD4, Jason M. Melear, MD5, Alexander I. Spira, PhD, MD, FACP6* , Jonah Shulman, MD7*, Sudhir Manda, MD8, John M. Burke, MD9 , Saurabh Chhabra, MD1, Jeff P. Sharman, MD10 , Amrita Krishnan, MD3, Nina Shah, MD11, Clifford DiLea, RPh, Pharm.D.12*, Jason Kuriakose, MBA13*, Craig Jerome Berman, MD13*, Shannon L. Matheny, PhD13*, John P. Leonard, MD14 and Arturo Molina, MD, MS13	3030 Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma https://ash.confex.com/ash/2020/webprogram/Paper139829.html	Session 626 USOR #17205	Monday, December 7, 2020, 7:00 AM-3:30 PM
Saulius K. Girnius, MD1, Habte A. Yimer, MD2, Stephen J. Noga, MD, PhD3, Sudhir Manda, MD4, Roger M. Lyons, MD5 , Kimberly Bogard, PharmD3*, Presley Whidden3*, Dasha Cherepanov3*, Vickie Lu, PhD3*, Jack Aiello, EE, MS, BS6*, Joshua R. Richter, MD7 and Robert M. Rifkin, MD8	3200 In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy Increases the Feasibility of Long-Term PI Treatment and Benefit for Newly Diagnosed Multiple Myeloma (NDMM) Patients in an Outpatient Setting: Updated Real-World Results from the Community-Based United States (US) MM-6 Study https://ash.confex.com/ash/2020/webprogram/Paper140482.html	Session 653 USOR #17081	Monday, December 7, 2020, 7:00 AM-3:30 PM

Bolded text: US Oncology Research affiliated investigator

*Denotes non-member of the American Society of Hematology

POSTER PRESENTATIONS

Authors	Title	Session #	Date/Time/ Location
Robert M. Rifkin, MD1 , Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD2*, Sebastian Grosicki, MD, PhD3, Kihyun Kim, MD, PhD4, Francesco Di Raimondo, MD5, Meletios A Dimopoulos6, Katja Weisel, MD7*, Bertrand Arnulf, MD8*, Roman Hajek, MD9, Vania T. M. Hungria, MD, PhD10, Andrew Spencer11, Randy Davis, PhD12*, Antonio Riccio, PhD, MBA13*, Chanbin Kim14*, Jodie Wilkes15*, Ruth Rutledge16*, Mala Talekar, MD17*, Brandon E. Kremer, MD, PhD17*, Ira Gupta, MD17* and Maria-Victoria Mateos, MD, PhD18	3247 DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) https://ash.confex.com/ash/2020/webprogram/Paper139181.html	Session 653 USOR #18230	Monday, December 7, 2020, 7:00 AM-3:30 PM
John M. Burke, MD1 , Nicholas Liu, PharmD2*, Kristina Yu-Isenberg, PhD, MPH, RPh2*, Michelle A. Fanale, MD2, Andy Surinach, MPH3*, Carlos Flores, MPH3*, Julie Lisano, PharmD2* and Tycel J. Phillips, MD4	3418 Real-World Characteristics of Patients with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching https://ash.confex.com/ash/2020/webprogram/Paper140832.html	Session 902	Monday, December 7, 2020, 7:00 AM-3:30 PM
Minoo Battiwalla, MD1,2, Carlos Bachier, MD2,3, Vikas Bhushan, MD2,4* , Michael J. Eckrich, MD, MPH2,5, Alireza Eghtedar, MD2,6*, Haydar Frangoul, MD2,7*, Suman Kambhampati, MD2,8*, Shahbaz Malik, MD2,9*, Peter A. McSweeney, MD2,6*, Jeremy Pantin, MBBS2,3, Aravind Ramakrishnan, MD2,9, Hana Safah, MD2,10, Paul J Shaughnessy, MD2,11, Betsy Blunk, BSN, RN, BMTCN2*, Tonya Cox, BSN, RN2, Rocky Billups, MS2 and Charles F. Lemaistre, MD2	3427 Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN) https://ash.confex.com/ash/2020/webprogram/Paper139121.html	Session 902	Monday, December 7, 2020, 7:00 AM-3:30 PM
Jennifer R Brown, MD, PhD1, John C. Byrd, MD2, Paolo Ghia, MD, PhD3, Jeff P. Sharman, MD4 , Peter Hillmen, MBChB, PhD, FRCP, FRCPath5, Deborah M. Stephens, DO6, Clare Sun, MD7, Wojciech Jurczak8*, John M. Pagel, MD PhD9, Alessandra Ferrajoli, MD10, Priti Patel, MD11, Marshall Baek11*, Tamara Lezhava11*, Nataliya Kuptsova-Clarkson, MD12*, Javid J. Moslehi, MD13* and Richard R. Furman, MD14	3146 Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL) https://ash.confex.com/ash/2020/webprogram/Paper134797.html	Session 642	Monday, December 7, 2020, 7:00 AM-3:30 PM
David Belada, MD, PhD1*, Grzegorz S. Nowakowski, MD2, Juan Miguel Bergua Burgues, MD3*, Marc André, MD4*, Katerina Kopeckova, MD5*, Don A. Stevens, MD6, Marek Trneny, MD, Prof7, Ernesto Perez Persona8*, Petra Pichler9*, Pia Klopfer10*, Bettina Brackertz10*, Emanuel Lohrmann, MD10*, Anirban Lahiry10*, Neha Shah10*, Gunter Fingerle-Rowson, MD, PhD10, Wolfram Brugger10* and John M. Burke, MD11	3028 A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase https://ash.confex.com/ash/2020/webprogram/Paper139788.html	Session 626 USOR #19015	Monday, December 7, 2020, 7:00 AM-3:30 PM
Justin M. Watts, MD1, Tara Lin, MD2, Eunice S. Wang, MD3, Alice S. Mims, MD4, Elizabeth H. Cull, MD5 , Prapti Patel, MD6, Paul J. Shami, MD7*, Roland B. Walter, MD, PhD, MS8, Christopher R. Cogle9, Ruth A. Chenault, MS10*, Bret Macpherson, MSc, MBA10*, Allison Given Chunyk10*, Catherine J. McMahan10*, Jane A. Gross, PhD10* and Scott Stromatt, MD10*	2858 Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome https://ash.confex.com/ash/2020/webprogram/Paper141619.html	Session 616	Monday, December 7, 2020, 7:00 AM-3:30 PM
Yuliya Linhares, MD1, Mitul D. Gandhi2 , Michael Chung3*, Jennifer Adeleye4*, David Ungar5 and Mehdi Hamadani, MD6	2107 Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma https://ash.confex.com/ash/2020/webprogram/Paper136614.html	Session 626	Sunday, December 6, 2020, 7:00 AM-3:30 PM

Bolded text: US Oncology Research affiliated investigator

*Denotes non-member of the American Society of Hematology

ORAL PRESENTATIONS

Authors	Title	Session #	Date/Time/ Location
Frederick Lansigan, MD1, David Jacob Andorsky, MD2 , Morton Coleman, MD, FACP3*, Abdullaheem Yacoub, MD4*, Jason M. Melear, MD5, Suzanne R. Fanning, DO6, Kathryn S. Kolibaba, MD7 , Christopher M. Reynolds, MD8*, Grzegorz S. Nowakowski, MD9, Mecide Gharibo, MD10, Erin Ahn, MS11*, Ju Li, PhD11*, Mathias J. Rummel, MD, PhD12* and Jeff P. Sharman, MD13	340 Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma https://ash.confex.com/ash/2020/webprogram/Paper134193.html	Session 623 USOR #13064	Sunday, December 6, 2020, 10:30 AM
Adam J. Olszewski, MD1, Abraham Avigdor, MD2,3, Sunil Babu4*, Itai Levi, MD5*, Uri Abadi2,6*, Houston Holmes7* , Matthew McKinney8, Ron McCord9*, Yuying Xie10*, Cindy Chen9*, Kati Sarouei9*, Naseer Qayum11*, Carol O'Hear9*, Gila Sellam12* and Herbert Eradat13	401 Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/ Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma https://ash.confex.com/ash/2020/webprogram/Paper136255.html	Session 626 USOR #18187	Sunday, December 6, 2020, 12:15 PM
Christopher A. Yasenachak, MD1 , Rodolfo Bordonì, MD2*, Dipti Patel-Donnelly, MD3, Timothy Larson, MD4* , Jerome Goldschmidt, MD5* , Ralph V. Boccia, MD6, Vivian J.M. Cline7* , Mariana Sacchi, MD8*, Andres Forero-Torres9*, Robert B. Sims, MD9, Jingmin Liu9* and Jonathan W. Friedberg, MD, MSc10	471 Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients https://ash.confex.com/ash/2020/webprogram/Paper136583.html	Session 624 USOR #11282	Sunday, December 6, 2020, 2:15 PM
John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci1, Wojciech Jurczak, MD, PhD2, Ryan Jacobs, MD3, Sebastian Grosicki, MD, PhD4, Krzysztof Giannopoulos, MD, PhD5, Tomasz Wrobel, MD PhD6, Syed F. Zafar, MD7, Jennifer L. Cultrera, MD8, Suman Kambhampati, MD9*, Alexey Danilov, MD10, John M. Burke, MD11, Jerome Goldschmidt, MD12* , Douglas F. Beach, MD13, Scott F. Huntington, MD, MPH14, Javier Pinilla Ibarz, MD, PhD15, Jeff P. Sharman, MD16 , Tanya Siddiqi, MD17, Danielle M. Brander, MD18, John M. Pagel, MD PhD19, Kathryn S. Kolibaba, MD20 , Monika Dlugosz-Danecka, MD, PhD2*, Nilanjan Ghosh, MD, PhD21, Peter Sportelli, BS 22, Hari P. Miskin, MSc22*, Owen A. O'Connor, MD, PhD22, Michael S. Weiss22* and Ian W. Flinn, MD, PhD23	543 Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/ Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study https://ash.confex.com/ash/2020/webprogram/Paper134783.html	Session 642 USOR #15229	Monday, December 7, 2020, 7:15 AM
Thierry Facon, MD1*, Christopher P. Venner2*, Nizar Bahlis, MD3, Fritz Offner, MD, PhD4, Darrell J. White, MD5, Lotfi Benboubker, MD6*, Sophie Rigauddau, MD7*, Philippe Rodon, MD8, Sung-Soo Yoon, MD, PhD9, Kenshi Suzuki, MD, PhD10, Hirohiko Shibayama, MD, PhD11, Xiaoquan Zhang, MD12*, Godwin Yung12*, Robert M. Rifkin, MD13 , Philippe Moreau14*, Sagar Lonial, MD15, Shaji K. Kumar, MD16, Paul G. Richardson, MD17 and S. Vincent Rajkumar, MD18	551 The Phase 3 TOURMALINE-MM2 Trial: Oral Ixazomib, Lenalidomide, and Dexamethasone (IRd) Vs Placebo-Rd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) https://ash.confex.com/ash/2020/webprogram/Paper137007.html	Session 653 USOR #12181	Monday, December 7, 2020, 7:45 AM
Anthony R. Mato, MD1, Jacqueline C. Barrientos, MD2, Jeff P. Sharman, MD3 , Danielle M. Brander, MD4, Meghan Gutierrez, BA5*, Karen Kadish, MSN6*, Israel Arango-Hisijara, MD7*, Sandhya Upasani7*, Jennifer Han, PharmD, MBA8*, Qing Huang, PhD8*, Reethi Iyengar, PhD7* and Nilanjan Ghosh, MD, PhD9	547 Real-World Prognostic Biomarker Testing, Treatment Patterns and Dosing Among 1461 Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the informCLL Prospective Observational Registry https://ash.confex.com/ash/2020/webprogram/Paper133798.html	Session 642 USOR #15005	Monday, December 7, 2020, 8:15 AM

Bolded text: US Oncology Research affiliated investigator

*Denotes non-member of the American Society of Hematology

To learn more, please contact
researchopportunities@mckesson.com

A McKesson Company

©2020 The US Oncology Network
SPO-834719-12-20

